Compare Gilead Sciences, Inc. (GILD) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Gilead Sciences, Inc. trades at $151.13 (market cap $182.40B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.85 (market cap $1.45B). The key difference: Gilead Sciences, Inc. is far larger — about 125.8× Direxion NASDAQ 100 Equal Weighted Index Shares's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Direxion NASDAQ 100 Equal Weighted Index Shares for 48 Days on average.
| GILD | QQQE | |
|---|---|---|
Market Cap | $182.40B | $1.45B |
Volume | 4,469,821 | 323,568 |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $124.69 |
52-Week Low | $116.74 | $96.06 |
Typical Hold Time | 111 Days | 48 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $151.17, up 2.94% recently, with strong technical momentum and bullish moving averages. The company shows robust revenue growth to $29.44B in 2025 and beat earnings estimates in three consecutive quarters, though net income margin turned negative at -10.64% for 2026. Recent developments include expanded HIV drug access in Latin America via a PAHO partnership, positioning Gilead for growth in its core franchises.
Gilead presents a mixed outlook with solid operational cash flow and analyst bullishness (65.5% buy ratings) offset by profitability concerns and high debt levels. The stock's current price aligns with the consensus target of $151.57, suggesting limited near-term upside. Key risks include execution in oncology pipeline expansion and reliance on HIV treatment revenues amid competitive pressures.
QQQE, the Direxion NASDAQ-100 Equal Weighted Index ETF, trades at $121.68, down 0.17% on the day. Technical indicators show a bullish trend with moving averages supporting upside momentum, while oscillators are neutral. The equal-weight strategy reduces technology concentration compared to the standard NASDAQ-100 ETF, offering diversified exposure to large-cap growth stocks. Recent news highlights tactical preference for QQQE over QQQ due to its fundamental and technical positioning.
The outlook for QQQE is positive, driven by its equal-weight approach mitigating single-stock risk and capturing broad Nasdaq growth. Key risks include market volatility and sector concentration shifts. Investment appeal lies in its structural diversification, though reliance on tech sector performance remains a factor for investors to weigh.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
